Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat, Pembrolizumab, and CRS-207 +/- GVAX in Metastatic Pancreatic Cancer
NCT03006302Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2018
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of epacadostat in pancreatic adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jan 2018; status: completed.
02
Drugs
epacadostat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03006302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006302.